BACKGROUND: Absence of clinical and radiological activity in relapsing-remitting multiple sclerosis (RRMS) is perceived as disease remission. We explored the role of persisting inflammation during remission in disease evolution. METHODS: Cerebrospinal fluid (CSF) levels of interleukin 1beta (IL-1beta), a major proinflammatory cytokine, were measured in 170 RRMS patients at the time of clinical and radiological remission. These patients were then followed up for at least 4 years, and clinical, magnetic resonance imaging (MRI) and optical coherence tomography (OCT) measures of disease progression were recorded. RESULTS: Median follow-up of RRMS patients was 5 years. Detection of CSF IL-1beta levels at the time of remission did not predict earlier relapse or new MRI lesion formation. Detection of IL-1beta in the CSF was instead associated with higher progression index (PI) and Multiple Sclerosis Severity Scale (MSSS) scores at follow-up, and the number of patients with sustained Expanded Disability Status Scale (EDSS) or Multiple Sclerosis Functional Composite worsening at follow-up was higher in individuals with detectable levels of IL-1beta. Patients with undetectable IL-1beta in the CSF had significantly lower PI and MSSS scores and a higher probability of having a benign MS phenotype. Furthermore, patients with undetectable CSF levels of IL-1beta had less retinal nerve fiber layer thickness and macular volume alterations visualized by OCT compared to patients with detectable IL-1beta. CONCLUSIONS: Our results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression. Detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients.

Rossi, S., Studer, V., Motta, C., Germani, G., Macchiarulo, G., Buttari, F., et al. (2014). Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. JOURNAL OF NEUROINFLAMMATION, 11(1), 32-32 [10.1186/1742-2094-11-32].

Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis

BUTTARI, FABIO;MANCINO, RAFFAELE;CENTONZE, DIEGO
2014-02-18

Abstract

BACKGROUND: Absence of clinical and radiological activity in relapsing-remitting multiple sclerosis (RRMS) is perceived as disease remission. We explored the role of persisting inflammation during remission in disease evolution. METHODS: Cerebrospinal fluid (CSF) levels of interleukin 1beta (IL-1beta), a major proinflammatory cytokine, were measured in 170 RRMS patients at the time of clinical and radiological remission. These patients were then followed up for at least 4 years, and clinical, magnetic resonance imaging (MRI) and optical coherence tomography (OCT) measures of disease progression were recorded. RESULTS: Median follow-up of RRMS patients was 5 years. Detection of CSF IL-1beta levels at the time of remission did not predict earlier relapse or new MRI lesion formation. Detection of IL-1beta in the CSF was instead associated with higher progression index (PI) and Multiple Sclerosis Severity Scale (MSSS) scores at follow-up, and the number of patients with sustained Expanded Disability Status Scale (EDSS) or Multiple Sclerosis Functional Composite worsening at follow-up was higher in individuals with detectable levels of IL-1beta. Patients with undetectable IL-1beta in the CSF had significantly lower PI and MSSS scores and a higher probability of having a benign MS phenotype. Furthermore, patients with undetectable CSF levels of IL-1beta had less retinal nerve fiber layer thickness and macular volume alterations visualized by OCT compared to patients with detectable IL-1beta. CONCLUSIONS: Our results suggest that persistence of a proinflammatory environment in RRMS patients during clinical and radiological remission influences midterm disease progression. Detection of IL-1beta in the CSF at the time of remission appears to be a potential negative prognostic factor in RRMS patients.
18-feb-2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Rossi, S., Studer, V., Motta, C., Germani, G., Macchiarulo, G., Buttari, F., et al. (2014). Cerebrospinal fluid detection of interleukin-1beta in phase of remission predicts disease progression in multiple sclerosis. JOURNAL OF NEUROINFLAMMATION, 11(1), 32-32 [10.1186/1742-2094-11-32].
Rossi, S; Studer, V; Motta, C; Germani, G; Macchiarulo, G; Buttari, F; Mancino, R; Castelli, M; De Chiara, V; Weiss, S; Martino, G; Furlan, R; Centonz...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis..pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 432.86 kB
Formato Adobe PDF
432.86 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/83667
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 70
  • ???jsp.display-item.citation.isi??? 63
social impact